Resumen
Recurrent and metastatic head and neck cancer has limited treatment options and survival time is measured in months. Toll-like receptor agonists have been shown to improve tumor immune responses in preclinical studies and several clinical trials have now been performed. We performed a meta-analysis of existing clinical trials for recurrent and metastatic head and neck cancer and found there was no treatment benefit of these agents. While they do not appear to cause more adverse events, additional clinical trials may need to focus on new agents or drug combinations.